Oncocyte Corp Files Definitive Proxy Statement
Ticker: IMDX · Form: DEF 14A · Filed: May 14, 2025 · CIK: 1642380
Sentiment: neutral
Topics: proxy-statement, sec-filing
TL;DR
Onco files proxy statement, no fee. All good.
AI Summary
Oncocyte Corp filed a Definitive Proxy Statement (DEF 14A) on May 14, 2025. The filing indicates no fee was required for this submission. The company's principal executive offices are located at 15 Cushing, Irvine, CA 92618, with a business phone number of 949-409-7600.
Why It Matters
This filing is a routine but essential disclosure for shareholders, providing information related to upcoming shareholder meetings and voting matters.
Risk Assessment
Risk Level: low — This is a standard regulatory filing (DEF 14A) with no immediate financial or operational news.
Key Players & Entities
- Oncocyte Corp (company) — Registrant
- 15 Cushing, Irvine, CA 92618 (location) — Business Address
- 949-409-7600 (phone_number) — Business Phone
FAQ
What type of filing is this?
This is a Definitive Proxy Statement (DEF 14A).
When was this filing submitted?
The filing was submitted on May 14, 2025.
What is Oncocyte Corp's business address?
Oncocyte Corp's business address is 15 Cushing, Irvine, CA 92618.
Is there a filing fee associated with this document?
No fee was required for this filing.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 14, 2025 regarding Oncocyte Corp (IMDX).